A study of immune markers in advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that cannot be cured with current treatments.
- You have not been found to have a genetic change (driver mutation) in genes like EGFR, ALK, or BRAF that would allow you to take a targeted pill.
- Your tumor has a PD-L1 level below 50% (a marker that can influence how well immunotherapy works).
- You have not yet had any treatment for your cancer, and you are about to start immunotherapy or chemo-immunotherapy (Cohort A), OR you have already had immunotherapy and the cancer has grown, and you are ready for a new treatment (Cohort B).
- You have enough tumor tissue available from a previous biopsy, or you are willing to have a new biopsy before or during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.